What does DR. FRANK LIPPENS MAXFAC do?

DR. FRANK LIPPENS MAXFAC is a specialist medical practice in Gent. Private Limited, started on 15 October 2009, 1 establishment.

What is the address of DR. FRANK LIPPENS MAXFAC?

The registered office of DR. FRANK LIPPENS MAXFAC is located at Onderbergen 60/0101, 9000 Gent.

Is DR. FRANK LIPPENS MAXFAC still active?

Yes. According to the CBE (18 September 2026) DR. FRANK LIPPENS MAXFAC is active, legal situation “Normale toestand”, started on 15 October 2009.

Is DR. FRANK LIPPENS MAXFAC registered on Peppol?

No, DR. FRANK LIPPENS MAXFAC is currently not registered on the Peppol network.

What is the enterprise number of DR. FRANK LIPPENS MAXFAC?

The enterprise number of DR. FRANK LIPPENS MAXFAC is BE0819680682.

When was DR. FRANK LIPPENS MAXFAC founded?

DR. FRANK LIPPENS MAXFAC was founded on 15 October 2009.

Who are the directors of DR. FRANK LIPPENS MAXFAC?

According to the 2025 annual accounts, the directors of DR. FRANK LIPPENS MAXFAC are: Frank Lippens.

Is DR. FRANK LIPPENS MAXFAC a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 October 2009; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. FRANK LIPPENS MAXFAC make in 2025?

DR. FRANK LIPPENS MAXFAC posted a profit after taxes of € 3,178 in financial year 2025.

What is the revenue of DR. FRANK LIPPENS MAXFAC?

As a small company, DR. FRANK LIPPENS MAXFAC is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 38,372.

DR. FRANK LIPPENS MAXFAC (Private Limited) - Gent

Dossier DR. FRANK LIPPENS MAXFAC, printed on 18 September 2026 from databakkes.be/en/0819680682/dr-frank-lippens-maxfac. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

DR. FRANK LIPPENS MAXFAC from Gent, company number BE0819680682, closed financial year 2025 with a result of € 3,178 after tax. For that financial year DR. FRANK LIPPENS MAXFAC recorded a gross margin of € 38,372 and equity of € 560,706. Compared with financial year 2024, the result moved from € 27,587 to € 3,178. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 19, 2025.

What it is worth Growing

€ 560,706

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 3,178

▼ 88% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 19,548

▼ 78% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 542,106.

People and assets in 2025

Vehicles and equipment

€ 218

▼ 69% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 192,872

▼ 17% vs 2024

€ 15,503 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 6,583

▲ 137% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,725

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 148,890 Gross margin 2022: € 148,890 First fiscal year in the series	€ 116,789 Gross margin 2023: € 116,789 ▼ 22% vs 2022 (€ 148,890) Unfavourable step	€ 83,057 Gross margin 2024: € 83,057 ▼ 29% vs 2023 (€ 116,789) Unfavourable step	€ 38,372 Gross margin 2025: € 38,372 ▼ 54% vs 2024 (€ 83,057) Unfavourable step	▼ 54%
Profit after taxes	€ 78,910 Profit after taxes 2022: € 78,910 First fiscal year in the series	€ 60,498 Profit after taxes 2023: € 60,498 ▼ 23% vs 2022 (€ 78,910) Unfavourable step	€ 27,587 Profit after taxes 2024: € 27,587 ▼ 54% vs 2023 (€ 60,498) Unfavourable step	€ 3,178 Profit after taxes 2025: € 3,178 ▼ 88% vs 2024 (€ 27,587) Unfavourable step	▼ 88%
Equity	€ 519,444 Equity 2022: € 519,444 First fiscal year in the series	€ 579,942 Equity 2023: € 579,942 ▲ 12% vs 2022 (€ 519,444) Favourable step	€ 557,529 Equity 2024: € 557,529 ▼ 4% vs 2023 (€ 579,942) Unfavourable step	€ 560,706 Equity 2025: € 560,706 ▲ 1% vs 2024 (€ 557,529) Favourable step	▲ 1%
Total debts	€ 351,112 Total debts 2022: € 351,112 First fiscal year in the series	€ 343,786 Total debts 2023: € 343,786 ▼ 2% vs 2022 (€ 351,112) Favourable step	€ 273,352 Total debts 2024: € 273,352 ▼ 20% vs 2023 (€ 343,786) Favourable step	€ 219,561 Total debts 2025: € 219,561 ▼ 20% vs 2024 (€ 273,352) Favourable step	▼ 20%
Cash	€ 12,161 Cash 2022: € 12,161 First fiscal year in the series	€ 11,279 Cash 2023: € 11,279 ▼ 7% vs 2022 (€ 12,161) Unfavourable step	€ 90,595 Cash 2024: € 90,595 ▲ € 79,315 vs 2023 (€ 11,279) Favourable step	€ 19,548 Cash 2025: € 19,548 ▼ 78% vs 2024 (€ 90,595) Unfavourable step	▼ 78%
Retained profit	€ 500,844 Retained profit 2022: € 500,844 First fiscal year in the series	€ 561,342 Retained profit 2023: € 561,342 ▲ 12% vs 2022 (€ 500,844) Favourable step	€ 538,929 Retained profit 2024: € 538,929 ▼ 4% vs 2023 (€ 561,342) Unfavourable step	€ 542,106 Retained profit 2025: € 542,106 ▲ 1% vs 2024 (€ 538,929) Favourable step	▲ 1%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 50,000 Dividend 2024: € 50,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 50,000) Unchanged	▼ 100%
Bank debt	€ 327,304 Bank debt 2022: € 327,304 First fiscal year in the series	€ 322,202 Bank debt 2023: € 322,202 ▼ 2% vs 2022 (€ 327,304) Favourable step	€ 233,770 Bank debt 2024: € 233,770 ▼ 27% vs 2023 (€ 322,202) Favourable step	€ 192,872 Bank debt 2025: € 192,872 ▼ 17% vs 2024 (€ 233,770) Favourable step	▼ 17%
Balance sheet total	€ 1,031,221 Balance sheet total 2022: € 1,031,221 First fiscal year in the series	€ 1,084,394 Balance sheet total 2023: € 1,084,394 ▲ 5% vs 2022 (€ 1,031,221) Unchanged	€ 991,546 Balance sheet total 2024: € 991,546 ▼ 9% vs 2023 (€ 1,084,394) Unchanged	€ 940,934 Balance sheet total 2025: € 940,934 ▼ 5% vs 2024 (€ 991,546) Unchanged	▼ 5%

Key figures of DR. FRANK LIPPENS MAXFAC, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 December 2026.

What happened to DR. FRANK LIPPENS MAXFAC?

What happened at DR. FRANK LIPPENS MAXFAC in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 19, 2025 New annual accounts for financial year 2025: profit of € 3,178 (▼ 88% vs 2024). Source: NBB ↗
2023 Frank Lippens became a director. NBB
Oct 27, 2009 New establishment in Gent. KBO
Oct 15, 2009 Start of the company according to the CBE. KBO

In short

From € 78,910 profit in 2022 to € 3,178 profit in 2025.

Paid € 82,688 in corporate taxes since 2022.

Best year ever: 2022, with € 78,910 profit.

Paid out € 50,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. FRANK LIPPENS MAXFAC? We notify you, reason included.

Follow DR. FRANK LIPPENS MAXFAC

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Frank Lippens

DR. FRANK LIPPENS MAXFAC

Drs. F. Lippens 100%

Behind DR. FRANK LIPPENS MAXFAC is Frank Lippens. It owns 100% of Drs. F. Lippens itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Frank Lippens

Director

Also active at: Scheldemeersen

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Onderbergen 60/0101

9000 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0819.680.682
VAT number: BE 0819.680.682
Registered office: Onderbergen 60/0101, 9000 Gent
Names & denominations: DR. FRANK LIPPENS MAXFAC
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 15 October 2009
Peppol: Not registered
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗